Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis

Linxuan Wei, Xiaolin Liu, Wenjing Zhang, Yuyan Wei, Yingwei Li, Qing Zhang, Ruifen Dong, Jungeun Sarah Kwon, Zhaojian Liu, Wenxin - Zheng, Beihua Kong

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The high-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor highly expressed in fetal tissue and malignant tumors but rarely detected within normal adult tissues. The clinical implications and biological functions of HMGA2 in endometrial carcinoma are largely unknown. Here we report that HMGA2 expression was barely detected in benign endometrium samples (2 of 28 samples). However, HMGA2 expression increased significantly from precancerous lesion endometrial glandular dysplasia (7 of 17, 41.2%), to serous endometrial intraepithelial carcinoma (5 of 8, 62.5%) and to full blown endometrial serous carcinoma (39 of 59, 66.1%). Functional characterization of HMGA2 revealed that the gene has both tumor growth promotion and metastasis. In addition, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin. Furthermore, HMGA2 overexpression started from endometrial serous precancers, non-invasive cancers, as well as in full blown carcinomas in a p53 knockout mouse model we recently established in our laboratory. Our findings suggest that HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial serous cancer and its precursor lesions.

Original languageEnglish (US)
Pages (from-to)249-259
Number of pages11
JournalAmerican Journal of Cancer Research
Volume6
Issue number2
StatePublished - 2016

Fingerprint

High Mobility Group Proteins
Carcinogenesis
Endometrial Neoplasms
Catenins
Neoplasms
Epithelial-Mesenchymal Transition
Carcinoma in Situ
Vimentin
Endometrium
Knockout Mice
Chromatin
Fetus
Neoplasm Metastasis
Carcinoma

Keywords

  • EMT
  • Endometrial serous carcinoma
  • HMGA2
  • Metastasis
  • Tumor growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wei, L., Liu, X., Zhang, W., Wei, Y., Li, Y., Zhang, Q., ... Kong, B. (2016). Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. American Journal of Cancer Research, 6(2), 249-259.

Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. / Wei, Linxuan; Liu, Xiaolin; Zhang, Wenjing; Wei, Yuyan; Li, Yingwei; Zhang, Qing; Dong, Ruifen; Kwon, Jungeun Sarah; Liu, Zhaojian; Zheng, Wenxin -; Kong, Beihua.

In: American Journal of Cancer Research, Vol. 6, No. 2, 2016, p. 249-259.

Research output: Contribution to journalArticle

Wei, L, Liu, X, Zhang, W, Wei, Y, Li, Y, Zhang, Q, Dong, R, Kwon, JS, Liu, Z, Zheng, W & Kong, B 2016, 'Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis', American Journal of Cancer Research, vol. 6, no. 2, pp. 249-259.
Wei, Linxuan ; Liu, Xiaolin ; Zhang, Wenjing ; Wei, Yuyan ; Li, Yingwei ; Zhang, Qing ; Dong, Ruifen ; Kwon, Jungeun Sarah ; Liu, Zhaojian ; Zheng, Wenxin - ; Kong, Beihua. / Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. In: American Journal of Cancer Research. 2016 ; Vol. 6, No. 2. pp. 249-259.
@article{d7cba6fc2cc74af5b4725b09a2fd888d,
title = "Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis",
abstract = "The high-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor highly expressed in fetal tissue and malignant tumors but rarely detected within normal adult tissues. The clinical implications and biological functions of HMGA2 in endometrial carcinoma are largely unknown. Here we report that HMGA2 expression was barely detected in benign endometrium samples (2 of 28 samples). However, HMGA2 expression increased significantly from precancerous lesion endometrial glandular dysplasia (7 of 17, 41.2{\%}), to serous endometrial intraepithelial carcinoma (5 of 8, 62.5{\%}) and to full blown endometrial serous carcinoma (39 of 59, 66.1{\%}). Functional characterization of HMGA2 revealed that the gene has both tumor growth promotion and metastasis. In addition, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin. Furthermore, HMGA2 overexpression started from endometrial serous precancers, non-invasive cancers, as well as in full blown carcinomas in a p53 knockout mouse model we recently established in our laboratory. Our findings suggest that HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial serous cancer and its precursor lesions.",
keywords = "EMT, Endometrial serous carcinoma, HMGA2, Metastasis, Tumor growth",
author = "Linxuan Wei and Xiaolin Liu and Wenjing Zhang and Yuyan Wei and Yingwei Li and Qing Zhang and Ruifen Dong and Kwon, {Jungeun Sarah} and Zhaojian Liu and Zheng, {Wenxin -} and Beihua Kong",
year = "2016",
language = "English (US)",
volume = "6",
pages = "249--259",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis

AU - Wei, Linxuan

AU - Liu, Xiaolin

AU - Zhang, Wenjing

AU - Wei, Yuyan

AU - Li, Yingwei

AU - Zhang, Qing

AU - Dong, Ruifen

AU - Kwon, Jungeun Sarah

AU - Liu, Zhaojian

AU - Zheng, Wenxin -

AU - Kong, Beihua

PY - 2016

Y1 - 2016

N2 - The high-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor highly expressed in fetal tissue and malignant tumors but rarely detected within normal adult tissues. The clinical implications and biological functions of HMGA2 in endometrial carcinoma are largely unknown. Here we report that HMGA2 expression was barely detected in benign endometrium samples (2 of 28 samples). However, HMGA2 expression increased significantly from precancerous lesion endometrial glandular dysplasia (7 of 17, 41.2%), to serous endometrial intraepithelial carcinoma (5 of 8, 62.5%) and to full blown endometrial serous carcinoma (39 of 59, 66.1%). Functional characterization of HMGA2 revealed that the gene has both tumor growth promotion and metastasis. In addition, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin. Furthermore, HMGA2 overexpression started from endometrial serous precancers, non-invasive cancers, as well as in full blown carcinomas in a p53 knockout mouse model we recently established in our laboratory. Our findings suggest that HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial serous cancer and its precursor lesions.

AB - The high-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor highly expressed in fetal tissue and malignant tumors but rarely detected within normal adult tissues. The clinical implications and biological functions of HMGA2 in endometrial carcinoma are largely unknown. Here we report that HMGA2 expression was barely detected in benign endometrium samples (2 of 28 samples). However, HMGA2 expression increased significantly from precancerous lesion endometrial glandular dysplasia (7 of 17, 41.2%), to serous endometrial intraepithelial carcinoma (5 of 8, 62.5%) and to full blown endometrial serous carcinoma (39 of 59, 66.1%). Functional characterization of HMGA2 revealed that the gene has both tumor growth promotion and metastasis. In addition, HMGA2 induced epithelial-mesenchymal transition (EMT) through modulation vimentin and β-catenin. Furthermore, HMGA2 overexpression started from endometrial serous precancers, non-invasive cancers, as well as in full blown carcinomas in a p53 knockout mouse model we recently established in our laboratory. Our findings suggest that HMGA2 may serve as a useful diagnostic marker in the assessment of endometrial serous cancer and its precursor lesions.

KW - EMT

KW - Endometrial serous carcinoma

KW - HMGA2

KW - Metastasis

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=84981763309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981763309&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84981763309

VL - 6

SP - 249

EP - 259

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 2

ER -